Cabozantinib with immune checkpoint inhibitor versus cabozantinib monotherapy in patients with metastatic clear cell renal cell carcinoma progressing after prior immune checkpoint inhibitor

Ähnliche Einträge

• A pan‐tumor review of the role of poly(adenosine diphosphate ribose) polymerase inhibitors
  von: Chadi Hage Chehade, et al.
  Veröffentlicht: (2025)
• Tissue‐resident memory T cells in immunotherapy and immune‐related adverse events by immune checkpoint inhibitor
  von: Hao Xiong, et al.
  Veröffentlicht: (2024)
• Rechallenge of immune checkpoint inhibitors in advanced non‐small cell lung cancer
  von: Gen Lin, et al.
  Veröffentlicht: (2024)
• The effect of common medications on the efficacy of immune checkpoint inhibitors
  von: Daria Brinzevich, et al.
  Veröffentlicht: (2025)
• Red blood cell alloimmunization: A new checkpoint inhibitor immune‐related adverse event?
  von: Lianne Rotin, et al.
  Veröffentlicht: (2025)